Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas


Purpose:

ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer


Criteria:

Inclusion Criteria: - Men and women ≥ 18 years of age - ECOG performance status of 0 or 1 - Histologically or cytologically confirmed advanced pancreatic ductal adenocarcinoma that is unresectable or metastatic - Prior therapy with ≥ 1 systemic chemotherapy regimen for unresectable or metastatic pancreatic cancer or unwilling/unable to receive systemic chemotherapy Exclusion Criteria: - Prior malignancy (other than pancreatic cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to < 2 years. - Known central nervous system (CNS) metastases and/or carcinomatous meningitis - Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening - Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction - Breastfeeding or pregnant


NCT ID:

NCT02362048


Primary Contact:

Study Director
Linda Bavisotto, MD FACP
Acerta Pharma


Backup Contact:

N/A


Location Contact:

Houston, Texas
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.